Simulations PlusSLP +0.22%81 EBITDA Margin % is 29.55% as of Feb. 2026, which is 14% below its 10-year median of 34.40. GuruFocus rates SLP with a GF Score™ of 81/100 and a GF Value™ of $38.31 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Simulations Plus ranks better than 75.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Simulations Plus's EBITDA for the
three
months ended in Feb. 2026 was $7.18 Mil. Simulations Plus's Revenue for the
three
months ended in Feb. 2026 was $24.29 Mil. Therefore, Simulations Plus's EBITDA margin for the quarter that ended in Feb. 2026 was 29.55%.
Simulations Plus (NAS:SLP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Simulations Plus EBITDA Margin % Related Terms
Simulations Plus EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Simulations Plus's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLP vs TBRG, CARL, NRC: EBITDA Margin % Comparison
For the Health Information Services subindustry, Simulations Plus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Simulations Plus's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (SLP) has a EBITDA Margin % of 29.55% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Simulations Plus and its competitors. This is 14% below median its historical median of 34.40. Over the past decade, Simulations Plus' EBITDA Margin % has ranged from 16.85 to 45.91. According to the industry distribution chart, Simulations Plus ranks #164 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 24.7%.
Is Simulations Plus' EBITDA Margin % too high?
Simulations Plus' current EBITDA Margin % of 29.55% is 14% below median its 10-year median of 34.40. Over the past 10 years, this metric has ranged from a low of 16.85 to a high of 45.91. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Simulations Plus' value of 29.55% is 189.4% above this industry median. Based on the distribution chart, Simulations Plus ranks #164 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Simulations Plus has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' EBITDA Margin % compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #164 out of 664 companies for EBITDA Margin %. This places Simulations Plus in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Simulations Plus' value of 29.55% is 189.4% above this benchmark. Historically, Simulations Plus' own EBITDA Margin % has ranged from 16.85 to 45.91 over the past decade. While the company's 10-year median is 34.40 vs. the industry median of 10.21, Simulations Plus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current EBITDA Margin % of 29.55% is 189.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current EBITDA Margin % is 29.55%, which is 14% below median its own 10-year median of 34.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $38.31, compared to a current price of $18.38 — trading 52% below its estimated fair value. The current EBITDA Margin % is 29.55%, which is 14% below median its 10-year median of 34.40 and 189.4% above the Healthcare Providers & Services industry median of 10.21. Simulations Plus' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Simulations Plus (SLP), the current EBITDA Margin % is 29.55% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.38 is trading 52% below its estimated GF Value™ of $38.31.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
EBITDA Margin %: 29.55% (14% below median its 10-year median of 34.40)
GF Value™: $38.31 vs. price of $18.38 (52% below fair value)
Industry Position: 189.4% above the Healthcare Providers & Services median (#164 of 664)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
81GF Score
Get the complete analysis for SLP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
